For the quarter ending 2026-03-31, TMCI made $47,198K in revenue. -$18,059K in net income. Net profit margin of -38.26%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 47,198 | 62,519 | 50,214 | 47,387 |
| Cost of goods sold | 9,791 | 12,118 | 10,508 | 9,635 |
| Gross profit | 37,407 | 50,401 | 39,706 | 37,752 |
| Sales and marketing | 33,775 | 37,253 | 34,421 | 33,084 |
| Research and development | 4,622 | 4,542 | 4,680 | 5,498 |
| General and administrative | 16,177 | 14,528 | 16,281 | 16,144 |
| Total operating expenses | 54,574 | 56,323 | 55,382 | 54,726 |
| Loss from operations | -17,167 | -5,922 | -15,676 | -16,974 |
| Interest income | 501 | 527 | 634 | 775 |
| Interest expense | 1,570 | 1,350 | 1,338 | 1,321 |
| Debt extinguishment loss | - | -2,737 | - | - |
| Other income, net | 275 | 88 | 92 | 122 |
| Other non-operating income (expense), net | -794 | -3,472 | -612 | -424 |
| Net loss | -17,961 | -9,394 | -16,288 | -17,398 |
| Unrealized gain (loss) on marketable securities | -98 | -11 | 33 | -7 |
| Comprehensive loss | -18,059 | -9,405 | -16,255 | -17,405 |
| Basic EPS | -0.28 | -0.147 | -0.26 | -0.28 |
| Diluted EPS | -0.28 | -0.147 | -0.26 | -0.28 |
| Basic Average Shares | 64,592,681 | 63,892,302 | 63,515,372 | 63,006,891 |
| Diluted Average Shares | 64,592,681 | 63,892,302 | 63,515,372 | 63,006,891 |
TREACE MEDICAL CONCEPTS, INC. (TMCI)
TREACE MEDICAL CONCEPTS, INC. (TMCI)